BioStock: Curasight targets prostate cancer with theranostic approach

Danish biotech company Curasight is developing its theranostic platform to target and assess the aggressiveness of cancer tumours. The technology recently showed promising results in an investigator-initiated phase II trial in prostate cancer. In this article, BioStock takes a closer look at the prostate cancer diagnostics landscape to gain insight into how the company intends to position its product candidate uTRACE.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/curasight-targets-prostate-cancer-with-theranostic-approach/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se